156 related articles for article (PubMed ID: 34987750)
1. Effectiveness of drug postmarketing all-case surveillance as a safety measure in Japan.
Kondo H; Masamune K
Ther Adv Drug Saf; 2021; 12():20420986211065215. PubMed ID: 34987750
[TBL] [Abstract][Full Text] [Related]
2. A Sponsor's Perspective on the Contribution of Regulatory-Required Observational Post-Marketing Studies to Understanding Human Drug Product Benefit/Risk in Japan.
Wolter KD; Kamatani A; Suzuki Y; Imaeda T; Dagher R; Safferman A; Junor R
Pharmaceut Med; 2024 May; 38(3):217-224. PubMed ID: 38555545
[TBL] [Abstract][Full Text] [Related]
3. Current situation and issues regarding termination of risk management plans in Japan.
Kameyama N; Hosaka A; Maeda H
Front Med (Lausanne); 2024; 11():1387652. PubMed ID: 38873195
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the safety evaluation for premarketing clinical trials of hemodialyzer and of postmarketing safety reports of hemodialyzer in Japan and the US: insights into the construction of a sophisticated premarketing evaluation.
Saito M; Iwasaki K
J Artif Organs; 2017 Mar; 20(1):62-70. PubMed ID: 27709305
[TBL] [Abstract][Full Text] [Related]
5. Postmarketing all-case surveillance trends and contribution to safety measures of drugs approved in Japan: a cross-sectional survey in 1999-2019.
Nakao M; Nakamura Y; Shimokawa M; Maeda H
Int J Clin Pharm; 2023 Feb; 45(1):108-116. PubMed ID: 36323961
[TBL] [Abstract][Full Text] [Related]
6. Postmarket safety communications on drugs approved in Japan: A 25-year analysis.
Tanaka Y; Tanaka M; Miyazawa H; Terashima R; Miyazawa M; Ikuma M; Tomita Y
Clin Transl Sci; 2024 Apr; 17(4):e13803. PubMed ID: 38651283
[TBL] [Abstract][Full Text] [Related]
7. Decision and timing of safety-related labeling changes for new drugs in Japan: Comparison with the United States and the European Union.
Fukuda K; Narukawa M
Pharmacoepidemiol Drug Saf; 2023 Dec; 32(12):1331-1340. PubMed ID: 37395168
[TBL] [Abstract][Full Text] [Related]
8. Analysis of safety-related regulatory actions by Japan's pharmaceutical regulatory agency.
Ishiguro C; Misu T; Iwasa E; Izawa T
Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1314-1320. PubMed ID: 28722235
[TBL] [Abstract][Full Text] [Related]
9. Possibility of Database Research as a Means of Pharmacovigilance in Japan Based on a Comparison with Sertraline Postmarketing Surveillance.
Hirano Y; Asami Y; Kuribayashi K; Kitazaki S; Yamamoto Y; Fujimoto Y
Value Health Reg Issues; 2018 May; 15():1-5. PubMed ID: 29474173
[TBL] [Abstract][Full Text] [Related]
10. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
[TBL] [Abstract][Full Text] [Related]
11. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of safety information obtained from postmarketing observational studies for re-examination in Japan.
Watanabe T; Narukawa M
Springerplus; 2016; 5(1):905. PubMed ID: 27386350
[TBL] [Abstract][Full Text] [Related]
13. A comparison of decision and timing of safety related labeling changes for new drugs approved both in Japan and the United States.
Hoshino Y; Narukawa M
Pharmacoepidemiol Drug Saf; 2021 May; 30(5):561-572. PubMed ID: 33559352
[TBL] [Abstract][Full Text] [Related]
14. Does Industry-Conducted All-Case Surveillance of Newly Approved Oncology Drugs Contribute to the Revision of Package Inserts in Japan?
Suzuki A; Sato H; Sasaki Y
Clin Transl Sci; 2019 Sep; 12(5):505-512. PubMed ID: 31062933
[TBL] [Abstract][Full Text] [Related]
15. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
Pflieger M; Bertram D
Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
[TBL] [Abstract][Full Text] [Related]
16. Overview of the Premarketing and Postmarketing Requirements for Drugs Granted Japanese Conditional Marketing Approval.
Matsushita S; Tachibana K; Kusakabe T; Hirayama R; Tsutsumi Y; Kondoh M
Clin Transl Sci; 2021 May; 14(3):806-811. PubMed ID: 33048440
[TBL] [Abstract][Full Text] [Related]
17. SAFETY PROFILE OF OCRIPLASMIN FOR SYMPTOMATIC VITREOMACULAR ADHESION: A Comprehensive Analysis of Premarketing and Postmarketing Experiences.
Hahn P; Chung MM; Flynn HW; Huang SS; Kim JE; Mahmoud TH; Sadda SR; Dugel PU
Retina; 2015 Jun; 35(6):1128-34. PubMed ID: 25635575
[TBL] [Abstract][Full Text] [Related]
18. Use of National Database of Health Insurance Claims and Specific Health Checkups for examining practical utilization and safety signal of a drug to support regulatory assessment on postmarketing drug safety in Japan.
Shida H; Kajiyama K; Sawada S; Ishiguro C; Kubo M; Kimura R; Hirano M; Komiyama N; Iguchi T; Oniyama Y; Uyama Y
Front Med (Lausanne); 2023; 10():1096992. PubMed ID: 36910503
[TBL] [Abstract][Full Text] [Related]
19. Regulatory approval pathways for anticancer drugs in Japan, the EU and the US.
Nagai S; Ozawa K
Int J Hematol; 2016 Jul; 104(1):73-84. PubMed ID: 27084259
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the new Japanese legislation for expedited approval of regenerative medicine products with the existing systems in the USA and European Union.
Jokura Y; Yano K; Yamato M
J Tissue Eng Regen Med; 2018 Feb; 12(2):e1056-e1062. PubMed ID: 28211195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
